Neurodegenerative disease models

Neurodegenerative diseases have remained some of most difficult diseases to treat.  Much of this stems from a lack of understanding of the underlying biology of the disease, as well as unreliable in vitro and animal models.  In recent months, costly late-stage clinical failures have derailed many companies from the struggle to find therapies. Hesperos, Inc. is committed to contributing its unique capabilities to ensure that no more companies are derailed. The company is making large strides to create low-cost accurate models to study these diseases, as well as give researchers key insights into potential therapies early.

Composite (1).jpg

alzheimer's disease 

Alzheimer’s disease (AD) is characterized by slow, progressive neurodegeneration leading to severe neurological impairment, but current drug development efforts are limited by the lack of robust, human-based disease models. Amyloid-β (Aβ) is known to play an integral role in AD progression as it has been shown to interfere with neurological function. However, studies into AD pathology commonly apply Aβ to neurons for short durations at non-physiological concentrations to induce an exaggerated dysfunctional phenotype. Such methods are unlikely to elucidate early-stage disease dysfunction, when treatment is still possible, since damage to neurons by these high concentrations is extensive. In this study, we investigated chronic, pathologically-relevant Aβ oligomer concentrations to induce an electrophysiological phenotype that is more representative of early AD progression compared to an acute high-dose application in human cortical neurons. The high, acute oligomer dose resulted in severe neuronal toxicity as well as upregulation of tau and phosphorylated tau. Chronic, low-dose treatment produced significant functional impairment without increased cell death or accumulation of tau protein. This in vitro phenotype more closely mirrors the status of early-stage neural decline in AD pathology and could provide a valuable tool to further understanding of early-stage AD pathophysiology and for screening potential therapeutic compounds.

WT ND41865 ACP_P5_Nestinr_Vimentin g_20X_1.jpg

amyotrophic lateral sclerosis (ALS) 

There has been a tremendous amount of research into the causes of Amyotrophic Lateral Sclerosis (ALS), but yet very few treatment options beyond amelioration of symptoms. A holistic approach has shown anecdotal evidence of slowing disease progression and this treatment, known as the Deanna Protocol (DP), postulates that ALS is a metabolic disease caused by glutamate that induces toxicity. In this study, glutamate exposure to human motoneurons was investigated and found not to significantly affect cell viability or electrophysiological properties. However, varicosities were observed in axons suggestive of transport impairment that was dose dependent for glutamate exposure. Surprisingly, a subset of the components of the DP eliminated these varicosities. To verify this finding a human SOD1 patient-derived iPSC line was examined and significant numbers of varicosities were present without glutamate treatment, compared to the iPSC control, indicating the possibility of a common mechanism despite different origins for the varicosities. Importantly, the DP ameliorated these varicosities by over 70% in the patient derived cells as well. These results are consistent with much of the literature on ALS and give hope for treatment not only for arresting disease progression using compounds considered safe but also the potential for restoration of function.